Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878240 | 0.76 | HRH4 (0.52) | KDM4EALDH1A1MAOBMAPTADORA2A | |
| SCHEMBL4574773 | 0.76 | ADORA2A (0.39) | KDM4EALDH1A1LMNAGAAMAOB | |
| SCHEMBL4869094 | 0.73 | HRH3 (0.41) | ADORA2AADORA1 | |
| SCHEMBL4816606 | 0.73 | THRB (0.47) | THRBKDM4EALDH1A1MAOBMAPT | |
| SCHEMBL4874208 | 0.71 | NPY5R (0.43) | THRBKDM4EALDH1A1LMNAGAA | |
| SCHEMBL2960591 | 0.69 | ADORA2A (0.60) | ALDH1A1ADORA2AADORA1MAOA | |
| SCHEMBL4879144 | 0.69 | NPY5R (0.43) | THRBKDM4EALDH1A1LMNAGAA | |
| SCHEMBL605852 | 0.69 | HRH4 (0.66) | THRB | |
| SCHEMBL3134958 | 0.68 | HSP90AA1 (0.49) | ALDH1A1ADORA2AADORA1 | |
| SCHEMBL603582 | 0.68 | HRH4 (0.68) | THRBKDM4EALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | THRB 4422/4885KDM4E 1709/4885ALDH1A1 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.